Patients treated with HES had lower functional fibrinogen MA than those treated Ringer 's acetate , which significantly increased the risk of subsequent bleeding [ HR 2.43 ( 1.16-5 .07 ) ] and possibly explained the excess bleeding with HES in the 6S trial .